Davide Griguolo

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio et al. · Cancer · 2019 · 149 citations · Full text

Medicine, Hematology, Pharmacology +10

AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Elisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla et al. · Cancer · 2023 · 48 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience

Eleonora De Bellis, Silvia Imbergamo, Anna Candoni et al. · Leukemia Research · 2022 · 27 citations · Full text

Medicine, Hematology, Oncology +13

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data

Francesca Palandri, Massimo Breccia, Mario Tiribelli et al. · Hematological Oncology · 2020 · 23 citations · Full text

Medicine, Hematology, Pharmacology +7

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto et al. · Leukemia Research · 2018 · 16 citations

Pharmacy, Pharmacology, Pharmacotherapy +5